Cancer Research on Prevention and Treatment    2021, Vol. 48 Issue (08) : 769-773     DOI: 10.3971/j.issn.1000-8578.2021.21.0296
|
Expression and Clinical Significance of miRNA-152 in Hepatocellular Carcinoma
PENG Qiliu1, WEI Shangmou1, ZHANG Lei1, GAN Liying1, XIE Zhen1, CHEN Qiaopei2, WEI Bangning3, ZHANG Zhi4#br#
1. Department of Clinical Laboratory, Guangxi International Zhuang Medicine Hospital, Nanning 530201, China; 2. Department of Clinical Laboratory, Maternity and Child Health Care of Guangxi Zhuang Autonomous Region, Nanning 530021, China; 3. Department of Hepatobiliary Surgery, Guangxi International Zhuang Medicine Hospital, Nanning 530201, China; 4. Department of Hepatobiliary Surgery, The First People’s Hospital of Nanning, Nanning 530022, China
Download: PDF(2996 KB)   ( 80 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Objective To investigate the expression of microRNA-152 in hepatocellular carcinoma, and analyze the correlation of miR-152 expression with the clinicopathological characteristics of hepatocellular carcinoma(HCC) patients. Methods Real-time PCR was used to detect the expression of miR-152 in tissue specimens from HCC and the adjacent non-cancerous hepatic tissues collected from 56 patients who underwent surgical treatment for primary HCC. The association between the expression of miR-152 and the clinical pathological characteristics and prognosis of HCC patients was analyzed. Results The relative expression of miR-152 in hepatocellular carcinoma and corresponding adjacent non-carcinoma tissues were 0.616±0.041 and 0.768±0.042 (P=0.011). The expression of miR-152 was significantly associated with TNM stages (P=0.042), tumor differentiation (P=0.035), metastasis (P=0.048) and venous invasion (P=0.042). There was no significant association between the miR-152 expression and gender, age, AFP level, tumor number or tumor grade. The OS (P=0.035) and PFS (P=0.012) in the low miR-152 expression group were obviously shorter than those in the high miR-152 expression group. Multivariate Cox regression analysis showed that the low expression of miR-152, tumor recurrence and pathological classification were significant independent prognostic factors for the prognosis of hepatocellular carcinoma patients. Conclusion The expression of miR-152 is decreased in hepatocellular carcinoma tissues, and the low expression of miR-152 is significantly associated with TNM stages, tumor differentiation, metastasis, venous invasion and the prognosis of HCC patients.
Keywords Hepatocellular carcinoma      MicroRNA-152      Overall survival      Prognosis     
ZTFLH:  R735.7  
Fund:Natural Science Foundation of Guangxi (No.2017JJA10583); Science and Technology Development Program of Nanning City (No. 20163126); 2019 Doctoral Research Fund of Guangxi University of Chinese Medicine (No. 2019BS042)
Issue Date: 18 August 2021
 Cite this article:   
PENG Qiliu,WEI Shangmou,ZHANG Lei, et al. Expression and Clinical Significance of miRNA-152 in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(08): 769-773.
 URL:  
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2021.21.0296
http://www.zlfzyj.com/EN/Y2021/V48/I08/769
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
PENG Qiliu
WEI Shangmou
ZHANG Lei
GAN Liying
XIE Zhen
CHEN Qiaopei
WEI Bangning
ZHANG Zhi
[1] Komoll RM, Hu Q, Olarewaju O, et al. MicroRNA-342-3p is
a potent tumour suppressor in hepatocellular carcinoma[J]. J
Hepatology, 2021, 74(1): 122-134.
[2] Wu J, Xie N, Xie K, et al. GPR48, a poor prognostic factor,
promotes tumor metastasis and activates β-catenin/TCF signaling
in colorectal cancer[J]. Carcinogenesis, 2013, 34(12): 2861-2869.
[3] 李自慧, 叶甲舟, 陈洁, 等. 解剖性肝切除术对合并微血管
侵犯的肝癌患者早期复发的影响[J]. 中华肝胆外科杂志,
2018, 24(1): 18-22. [Li ZH, Ye JZ, Chen J, et al. The impact
of anatomical resection for hepatocellular carcinoma with
microvascular invasion on early tumor recurrence [J]. Zhonghua
Gan Dan Wai Ke Za Zhi, 2018, 24(1): 18-22.]
[4] Brennan GP, Henshall DC. MicroRNAs as regulators of brain
function and targets for treatment of epilepsy[J]. Nat Rev Neurol,
2020, 16(9): 506-519.
[5] Wei L, Wang X, Lv L, et al. The emerging role of microRNAs
and long noncoding RNAs in drug resistance of hepatocellular
carcinoma[J]. Mol Cancer, 2019, 18(1): 147.
[6] Yang C, Zheng X, Ye K, et al. miR-135a Inhibits the Invasion
and Migration of Esophageal Cancer Stem Cells through the
Hedgehog Signaling Pathway by Targeting Smo[J]. Mol Ther
Nucleic Acids, 2020, 19: 841-852.
[7] Rezaei T, Amini M, Hashemi ZS, et al. microRNA-181 serves as a
dual-role regulator in the development of human cancers[J]. Free
Radic Biol Med, 2020, 152: 432-454.
[8] Weng J, Luo J, Cheng X, et al. Deletion of G protein-coupled
receptor 48 leads to ocular anterior segment dysgenesis (ASD)
through down-regulation of Pitx2[J]. Proc Natl Acad Sci USA,
2008, 105(16): 6081-6086.
[9] Shen K, Cao Z, Zhu R, et al. The dual functional role of
MicroRNA-18a (miR-18a) in cancer development[J]. Clin Transl
Med, 2019, 8(1): 32.
[10] Li B, Xie Z, Li B. miR-152 functions as a tumor suppressor in
colorectal cancer by targeting PIK3R3[J]. Tumour Biol, 2016,
37(8): 10075-10084.
[11] Liu Y, Gao S, Du Q, et al. miR-146a and miR-152 in prostate
cancer and clinicopathological parameters[J]. J BUON, 2019,
24(4): 1692-1699.
[12] Ghazanchaei A, Mansoori B, Mohammadi A, et al. Restoration
of miR-152 expr‍ession suppresses cell proliferation, survival, and
migration through inhibition of AKT-ERK pathway in colorectal
cancer[J]. J Cell Physiol, 2018, 234(1): 769-776.
[13] Yang D, Zhang Q. miR-152 may function as an early diagnostic
and prognostic biomarker in patients with cervical intraepithelial
neoplasia and patients with cervical cancer[J]. Oncol Lett, 2019,
17(6): 5693-5698.
[14] 汪毅, 袁伟, 马肖, 等. miR-152在结直肠癌组织中的表达及其与
预后的关系[J]. 中华肿瘤杂志, 2016, 38(10): 763-766. [Wang Y,
Yuan W, Ma X, et al. Expression of microRNA-152 in colorectal
cancer and its relationship with prognosis[J]. Zhonghua Zhong
Liu Za Zhi, 2016, 38(10): 763-766.]
[15] 张红森, 郭国营, 杨翠, 等. MiR-152在膀胱癌中的表达以及
对ERBB3/AKT2信号通路的调节作用[J]. 中国肿瘤, 2019,
28(1): 55-62. [Zhang HS, Guo GY, Yang C, et al. Expression of
MiR-152 in Bladder Cancer and Its Effect on ERBB3/Akt Signal
Pathway[J]. Zhongguo Zhong Liu, 2019, 28(1): 55-62.]
[16] Wang F, Ying H, He B, et al. Circulating miR-148/152 family as
potential biomarkers in hepatocellular carcinoma[J]. Tumour Biol,
2016, 37(4): 4945-4953.
[17] Dang YW, Zeng J, He RQ, et al. Effects of miR-152 on cell
growth inhibition, motility suppression and apoptosis induction in
hepatocellular carcinoma cells[J]. Asian Pac J Cancer Prev, 2014,
15(12): 4969-4976.
[18] Yin T, Liu MM, Jin RT, et al. miR-152-3p Modulates hepatic
carcinogenesis by targeting cyclin-dependent kinase 8[J]. Pathol
Res Pract, 2019, 215(6): 152406.
Related articles from Frontiers Journals
[1] LI Jinzhou, WANG Wenjie, YAO Yalong, MU Yanxi, CHEN Kang, SHEN Yimin, WANG Zhou, HUANG Zeping, CHEN Xiao. Development and Validation of Prognostic Nomogram Based on Negative Lymph Node Count for Patients with Gastric Signet Ring Cell Carcinoma#br#[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 923-930.
[2] HUANG Zhenghua, ZHOU Jian, LI Yufu, LIU Yanyan, ZHOU Keshu, SONG Yongping. Clinical Efficacy and Prognostic Factors of Autologous Hematopoietic Stem Cell Transplantation for Hodgkin’s Lymphoma in 38 Cases[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 952-955.
[3] XU XiaoFei, LI Yang, CHEN Lingyun, DAI Heyang, XUE Jiaojiao, LI Qingxia, . Research Progress of PNI and CONUT in Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 961-964.
[4] CAO Guangwen. Theoretical Update of Cancer Evo-Dev and Its Role in Targeted Immunotherapy for Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 747-755.
[5] JIA Lijuan, ZHANG Yunqiang, ZHANG Baihong, YUE Hongyun. Expression and Clinical Significance of m6A Methylatransferase ZC3H13 in Gastric Cancer Tissues and Serum[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 792-798.
[6] SUI Daxing, WANG Xueying, ZHANG Jiaxin. A New N-staging System for Predicting Postoperative Survival of M0 Stage Inflammatory Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 799-805.
[7] LI Jinzhou, HUANG Zeping, MU Yanxi, YAO Yalong, WANG Wenjie, LIU Haipeng, LIU Jie, WANG Zhou, CHEN Xiao. Prognostic Value of Negative Lymph Nodes Count in Solid Tumors[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 843-849.
[8] ZHOU Zhipeng, YANG Mingzhu, CAI Mingqin, XUE Juandi, LYU Xiaoyun. Mechanism of Astragaloside IV on HepG2 Cells Based on Molecular Dynamics Simulation and Experimental Evaluation[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 655-661.
[9] ZHOU Silei, SUN Guanqun, ZENG Tanlun, CHENG Zhuo, LIANG Xijun. Expression and Prognostic Value of CK2α' in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 662-666.
[10] XIA Lili, ZHU Xinyi, ZHANG Xiwei, LI Zhengjiang, LIU Shaoyan, LU Haizhen, AN Changming. Predictive Value of Depth of Invasion of Tongue Squamous Cell Carcinoma for Cervical Lymph Node Metastasis and Prognosis[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 675-681.
[11] ZHAN Jianghua, WANG Zhiru, . Progress and Comment on Surgical Treatment of Hepatoblastoma in Children[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 541-545.
[12] ZHOU Shi. Progress in Locoregional Interventional Therapy of Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 552-556.
[13] JIANG Mingting, HUANG Jing, ZHENG Shuping. Effects of Pin1 on Proliferation and Apoptosis of HepG2 Cells Under Endoplasmic Reticulum Stress[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 575-580.
[14] XU Huan, WANG Guangli, LI Tingming, WANG Wei, DONG Dandan. Transcriptome Analysis of Inhibitory Effect of Astaxanthin Against HepG2 Cell Lines[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 581-584.
[15] . Expression of MAD2L1 in Lung Adenocarcinoma and Its Effect on Immune Microenvironment[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 586-592.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed